LNTH
Lantheus Holdings, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | -1 | 6.70K | $264,917 | n/a | −1 |
| Q2 2026 | 130 | +6 | 56.22M | $5.58B | +14 | −7 |
| Q1 2026 | 126 | +6 | 62.19M | $3.90B | +10 | −5 |
| Q4 2025 | 120 | -2 | 60.97M | $3.47B | +2 | −3 |
| Q3 2025 | 20 | +2 | 33.16M | $1.70B | +2 | −1 |
| Q2 2025 | 16 | -2 | 29.15M | $2.39B | +1 | −3 |
| Q1 2025 | 15 | 0 | 7.80M | $761.04M | n/a | n/a |
| Q4 2024 | 15 | 0 | 6.76M | $604.90M | +2 | −2 |
| Q3 2024 | 14 | 0 | 4.84M | $531.32M | +1 | −1 |
| Q2 2024 | 14 | n/a | 5.72M | $459.02M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wealth Enhancement Advisory… | 6.70K | -13.7% | $264,917 | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Assenagon Asset Management… | $158.64M | was 0.1% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 401 holders, 70.59M shares, $5.23B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.